← Back
$NBY All transactions

NovaBay Pharmaceuticals, Inc.

C

$ Value

$0

Shares

56,806,080

Price

$0

Filed

Nov 3

Insider

Name

R01 Fund LP

Title

CIK

0001990517

Roles

10% Owner

Transaction Details

Transaction Date

2025-10-21

Code

C

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

56,806,080

Footnotes

This represents (i) the conversion of 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series D Preferred Stock") into 35,306,080 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock") and (ii) the conversion of 134,375 shares of the Issuer's Series E Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series E Preferred Stock") into 21,500,000 shares of the Issuer's Common Stock, both of which occurred on October 21, 2025 following stockholder approval at the Issuer's annual meeting on October 16, 2025 of proposals 5 and 9 set forth in the Issuer's Definitive Proxy Statement on Schedule 14A, filed by the Issuer with the Securities and Exchange Commission on September 23, 2025. | The reported securities may also be deemed to be beneficially owned by R01 Capital LLC ("R01 Capital"), R01 Capital Manager LLC ("R01 Capital Manager") and Michael Kazley ("Mr. Kazley" and together with R01 Capital, R01 Capital Manager and the Reporting Person, the "R01 Entities"), each of which or whom disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. R01 Capital is the general partner of the Reporting Person. R01 Capital Manager is the investment manager for R01 Capital. Mr. Kazley is the managing member of R01 Capital Manager. | On October 16, 2025, the Issuer issued and sold to the Reporting Person pre-funded warrants (the "Pre-Funded Warrants") to purchase an aggregate 2,702,703 shares of the Issuer's Common Stock. The purchase price was $1.10 per warrant, representing 110% of the closing price of the Common Stock on the day before the issuance, less the $0.01 exercise price for each warrant. The Pre-Funded Warrants have no expiration date and are exercisable for shares of Common Stock at any time after January 1, 2026, subject to receipt of stockholder approval.

Filing Info

Accession No.

0001437749-25-032855

Form Type

4

Issuer CIK

0001389545

R01 Fund LP's History

Date Ticker Type Value
2025-10-21 NBY C $0
2025-10-16 NBY A $0
2025-10-16 NBY A $0
2025-10-16 NBY $0

Other Insiders at NBY (90d)

Insider Bought Sold Last
Zheng Yenyou 2026-03-31
Freiman Paul E. 2026-03-31
Sit Swan 2026-03-31
Lazar David E. 2025-10-21
Law Tommy
Chief Financial Officer
2026-03-31
Kazley Michael John
Chief Executive Officer
2026-03-31